Five members of the UK Kidney Association have been recognised in the Top and Best Abstracts selected for presentation at the 2026 Congress of the European Renal Association (ERA) in Glasgow.

Two UKKA members are included in the Top 10 Abstracts:
Dr Jennifer Lees, for her national cohort study examining kidney-related adverse events associated with intravitreal VEGF inhibitor use in England, and Dr Thijs Jansz, for his analysis of kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors using UK primary care data.

Dr Jansz is also recognised within the Top 7 Abstracts presented by young authors, further highlighting the strength of his contribution in a highly competitive category.

Additional UKKA members recognised in the ERA Top and Best Abstracts selection include Dr Matthew Tabinor, Dr Rouvick Gama and Dr Katie Wong, whose work spans key areas of kidney research.

Dr Tabinor’s study focuses on improving risk stratification in CKD through the use of cystatin C alongside creatinine-based eGFR, with potential implications for more accurate assessment of kidney function and patient risk.

Dr Gama’s research, from the AIM CKD UK study, compares creatinine-based eGFR with measured GFR in a diverse multi-centre cohort, addressing ongoing challenges around accuracy and equity in kidney function measurement.

Dr Katie Wong’s abstract draws on data from the National Registry of Rare Kidney Diseases (RaDaR) to explore associations between genotype, proteinuria and kidney outcomes in Alport syndrome. Using longitudinal registry data, the work provides insight into disease progression in a rare inherited condition.

Dr Katie Wong will present her abstract at the ERA Congress on 5 June (16:00–17:00, M1 Room). Further details on the ERA 2026 scientific programme are available via the European Renal Association.

RaDaR is the UK’s national registry for rare kidney conditions and the largest of its kind globally, supporting research across the UK and internationally. It underpins studies on disease progression, trial readiness and treatment development, including recent work contributing to advances in rare kidney disease research and clinical trials.

The ERA Congress is a major international meeting in nephrology, with the Top and Best Abstracts forming part of the scientific programme in Glasgow this June.